skip to main content

SOLO-1 Results — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

EasyGynaecological CancersSOLO-1 ResultsSCE Medical Oncology

A 58-year-old woman with advanced ovarian cancer is being counselled about the SOLO-1 trial results. She has a germline BRCA1 mutation and is about to complete first-line platinum-taxane chemotherapy with a complete response. What was the median PFS with olaparib maintenance vs placebo in SOLO-1?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — 56 months vs 13.8 months

SOLO-1 demonstrated a dramatic PFS improvement with olaparib maintenance (median 56 months vs 13.8 months; HR 0.33) in BRCA-mutated advanced ovarian cancer after complete/partial response to first-line platinum-based chemotherapy. This represents one of the largest PFS benefits ever seen in a phase III oncology trial. Importantly, the 7-year follow-up showed that approximately 67% of olaparib-treated patients remained free of progression or death at 5 years.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer